Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
New Deal Could Be Worth Over $2.3bn
Executive Summary
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
You may also be interested in...
Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals
Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.
A Vaccines Renaissance, Spurred By COVID-19, Is Underway
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.
COVID-19 Boosts Sanofi's Ageing Lovenox Franchise, But Holds Back Travel Vaccine Sales
The COVID-19 pandemic led to a marked increase in sales of Sanofi’s LMW heparin, Lovenox, in the first quarter of 2021. The big pharma is also nearing late-stage clinical studies with two COVID-19 vaccine candidates.